AbbVie

2024 top biotech and pharma employers survey by Science magazine identifies leading companies in the industry

Sionna Therapeutics secures exclusive global rights to develop and commercialise advanced CF compounds, strengthening its pipeline…

Strategic shift to Skyrizi and Rinvoq strengthens AbbVie's dominance in immunology despite Humira's biosimilar competition

Skyrizi (risankizumab) and Rinvoq (upadacitinib) are emerging as key replacements as sharp declines are expected for Humira

The campaign seeks to educate the public about risk factors associated with glaucoma, and promote regular eye check-ups,…

Earlier this year, Pfizer acquired ADC giant Seagen for $43 billion in one of the largest M&A deals in industry history

Experts shed light on the prevalence of eye-related issues in today's digital age and dispelled common myths surrounding eye…

Market cap surged from $3.49 trillion during the first quarter (Q1) of 2023 to $3.56 trillion in Q2 2023

Lupin and AbbVie inked the licensing, development, and commercialisation agreement in 2018 for this novel oncology drug to treat…

It is expected that the prescribing patterns of Rinvoq by HCPs will follow an ongoing trend by gastroenterologists to be more…